InsidersTradesSigma
Discover the detailed record of transactions filed by Valantine Hannah, Director. Officer active across 2 companies, notably CareDx, Inc.. Aggregated, 7 disclosures have been recorded. Total volume traded: €44k. The latest transaction was disclosed on 16 June 2022 (Attribution). Regulator: SEC (Form 4). The full history is accessible without signup.
7 of 7 declarations
Hannah Valantine is a Director at CareDx, Inc. and BridgeBio Pharma, Inc. In these roles, she participates in the governance of the companies and strategic decision-making. Valantine brings her expertise and industry knowledge, which is essential for guiding growth and innovation initiatives. Her commitment to operational excellence is beneficial for both companies.